

COM-2025-008

3  
FEBRUARY  
2025

# PLEASE REVIEW Drug Information

PharmPix Clinical Department

## Drug Information:

Remember that medical literature is dynamic and is continuously changing as new scientific knowledge is developed. We exhort the frequent revision of treatment guidelines to assure that your recommendations are consistent with the most updated information.

It is our priority to offer high-quality services and support practices for health promotion and diseases prevention. If you have any questions or wish to have more information regarding this document, you can call us directly or view PharmPix communications online.

### QUESTIONS

Call us at 787-522-5252-ext 219.

Access our recent communications at our providers' portal:  
<https://www.pharmpix.com/providers/>.



PharmPix is committed to the health and wellness of our members.

The clinical team wants to communicate the latest up-to-date drug information requested.

## Ozempic Now Approved to Lower Kidney Disease Risk in Type 2 Diabetes

Novo Nordisk announced on January 28, 2025, that the U.S. Food and Drug Administration (FDA) has approved Ozempic® to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD).

### Background

Chronic kidney disease impacts around 37 million adults in the United States, and this number is projected to increase. It is a frequent complication of type 2 diabetes, with roughly 40% of individuals with type 2 diabetes also developing CKD.

Ozempic was first approved by the FDA in 2017 to help manage blood sugar levels in adults with type 2 diabetes. In 2020, the FDA expanded its approval to include reducing the risk of major cardiovascular events, such as heart attack, stroke, or death, in adults with type 2 diabetes who have existing heart disease.

### Clinical Study

The FDA's approval is based on data from the FLOW phase 3b kidney outcomes trial, which examined the impact of once-weekly 1 mg Ozempic injections on key kidney and cardiovascular outcomes in adults with type 2 diabetes and CKD.

The FLOW trial met its primary objective, showing that Ozempic reduced the relative risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death from cardiovascular disease by 24% (a 4.9% absolute risk reduction over 3 years) compared to a placebo, when added to standard treatment.

Adverse events that caused permanent discontinuation were more frequent in the semaglutide group compared to the placebo group, primarily due to gastrointestinal issues. However, serious adverse events were reported in fewer participants in the semaglutide group than in the placebo group.

Additional information can be found at: <https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea>.

If you have any questions or wish to have more information regarding this document, you can call us at 787-522-5252-ext. 219. Our pharmacists will help you. In addition, know that you can access our recent communications at our providers' portal: <https://www.pharmpix.com/providers/>.

PharmPix Drug Information Communication Number COM-2025-008 February 2025



**REFERENCES:**

1. Novo Nordisk. (2025, January 30). *FDA approves Ozempic to reduce kidney disease in type 2 diabetes*. <https://www.novonordisk-us.com/media/news-archive/news-details.html?id=915253>
2. AJMC. (2025, January 30). *FDA expands semaglutide use for CV, kidney risks in T2D, CKD*. <https://www.ajmc.com/view/fda-expands-semaglutide-use-for-cv-kidney-risks-in-t2d-ckd>



2 Street 1, Suite 500  
Guaynabo, PR 00968

Tel. 787.522.5252  
Fax 866.912.2830

[www.pharmpix.com](http://www.pharmpix.com)  
FRM-CL-000130-001



**CLINICAL PEARLS**  
BY PHARMPIX